Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 7556 pages

Showing 1 - 50


lymphoma

Mantle Cell Lymphoma: Addition of Venetoclax to Ibrutinib

As reported in The Lancet Oncology by Michael Wang, MD, and colleagues, the phase III SYMPATICO trial has shown that venetoclax/ibrutinib significantly improved progression-free survival vs placebo/ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL). Study Details In the...

skin cancer

Merkel Cell Carcinoma: Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Disease

As reported in the Journal of Clinical Oncology by Bhatia et al, nivolumab/ipilimumab did not produce better outcomes vs nivolumab alone in a cohort of immune checkpoint inhibitor (ICI)-naive patients with recurrent or metastatic Merkel cell carcinoma (MCC) enrolled in the phase I/II CheckMate 358...

colorectal cancer

ctDNA and Immunoscore in Resected Stage III Colon Cancer

As reported in the Journal of Clinical Oncology by Taieb et al, a combined analysis of two phase III adjuvant trials (IDEA-France and IDEA-Greece) in stage III colon cancer showed that the presence of circulating tumor DNA (ctDNA) after surgery was prognostic for poorer outcomes and that...

breast cancer

Annual vs Less Frequent Mammographic Surveillance in Breast Cancer Patients Aged ≥ 50 Years

In a UK phase III noninferiority trial (Mammo-50) reported in The Lancet, Dunn et al found that less frequent mammographic surveillance was noninferior to annual surveillance in outcomes among patients with breast cancer aged 50 years or older. Study Details In the multicenter trial, 5,235 women...

prostate cancer

Association of Acute and Late Toxicity in Radiotherapy for Prostate Cancer

In an individual patient data meta-analysis reported in The Lancet Oncology, Nikitas et al found that early toxicity associated with radiotherapy for prostate cancer was associated with increased risk for late toxicity. Study Details The study included patient-level data from six randomized phase...

colorectal cancer

Baseline Liquid Biopsy vs Tissue-Based Findings in Metastatic Colorectal Cancer

In an analysis reported in the Journal of Clinical Oncology, Stintzing et al found that baseline liquid biopsies identified RAS and BRAF mutations in patients with metastatic colorectal cancer considered RAS wild-type on the basis of tissue analyses. Study Details The study included patients from...

gynecologic cancers

ARIEL4: Rucaparib vs Chemotherapy for Relapsed Ovarian Cancer With Deleterious BRCA1 or BRCA2 Mutations

In an article in The Lancet Oncology, Oza et al presented the final overall survival analysis of the phase III ARIEL trial of rucaparib vs standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma. Study Details In the open-label trial, 349 patients from sites in 12...

breast cancer

Intratumoral Injection of mRNA-2752 and Pembrolizumab in High-Risk DCIS

In a single-institution phase I trial reported in JAMA Oncology, Ramalingam et al found that intratumoral injection of pembrolizumab and mRNA-2752 (a combination of interleukin [IL]-23, IL-36γ, and OX40L mRNAs) was active in patients with high-risk ductal carcinoma in situ (DCIS). Study Details Ten ...

lung cancer

Mobocertinib vs Platinum-Based Chemotherapy in First-Line Treatment of EGFR Exon 20 Insertion–Positive Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Jänne et al, an interim analysis of the phase III EXCLAIM-2 trial showed no progression-free survival benefit with mobocertinib—an EGFR tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion (ex20ins) mutations—compared with...

breast cancer

Weight Change and Heart Failure Risk After Breast Cancer Diagnosis

In a Republic of Korea nationwide cohort study reported as a research letter in JAMA Oncology, Jung et al found that weight increase following diagnosis of breast cancer was associated with increased risk of heart failure. Study Details The study used the National Health Insurance Service database...

breast cancer

Adjuvant T-DM1 vs Trastuzumab for Residual HER2-Positive Breast Cancer: Overall Survival in KATHERINE

As reported in The New England Journal of Medicine by Geyer et al, interim analysis of overall survival in the phase III KATHERINE trial showed a significant benefit of ado-trastuzumab emtansine (T-DM1) vs trastuzumab in patients with residual invasive HER2-positive breast cancer after neoadjuvant...

breast cancer

Pertuzumab Retreatment in HER2-Positive Locally Advanced/Metastatic Breast Cancer

As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed a significant benefit with the addition of pertuzumab retreatment to trastuzumab plus physician’s choice of chemotherapy (PTC) in patients with...

sarcoma

Botensilimab Plus Balstilimab in Relapsed or Refractory Metastatic Sarcomas

In a phase Ib study reported in the Journal of Clinical Oncology, Wilky et al found that the combination of botensilimab (Fc-enhanced anti–CTLA-4 antibody) and balstilimab (anti–PD-1 antibody) yielded activity in patients with relapsed or refractory metastatic sarcomas. Study Details In the trial,...

sarcoma

Discontinuation and Resumption of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

As reported in the Journal of Clinical Oncology by Mascarenhas et al, follow-up of a cohort of pediatric patients with TRK fusion sarcomas and related mesenchymal tumors treated with larotrectinib showed that discontinuation of treatment—with resumption for progressive disease—was associated with...

neuroendocrine tumors

Gastroenteropancreatic Neuroendocrine Tumor Incidence in the United States

In a study reported in a research letter in JAMA Oncology, Abboud et al found that the incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased in many organ sites during recent years in the United States. Study Details In the study, age-adjusted GEP-NETs incidence rates...

pancreatic cancer

Adjuvant Chemotherapy After Preoperative mFOLFIRINOX and Resection of Localized Pancreatic Adenocarcinoma

In a retrospective cohort study reported in JAMA Oncology, Stoop et al found that use of adjuvant modified leucovorin, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) and other multiagent chemotherapy regimens improved overall survival vs no adjuvant chemotherapy in patients with localized...

breast cancer

Trastuzumab/Pertuzumab Plus Eribulin or Taxane in Locally Advanced or Metastatic Breast Cancer

In a Japanese noninferiority phase III trial (EMERALD) reported in the Journal of Clinical Oncology, Yamashita et al found that the addition of eribulin to trastuzumab/pertuzumab (HP) was noninferior in progression-free survival vs the addition of a taxane to HP in the first-line treatment of...

colorectal cancer

Thermal Ablation vs Surgical Resection of Small Resectable Colorectal Liver Metastases

In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation was noninferior to surgical resection in terms of overall survival in patients with small resectable colorectal liver metastases. Study Details In...

head and neck cancer

Addition of Bevacizumab to Pembrolizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

In a Singaporean phase II trial reported in The Lancet Oncology, Chong et al found that the addition of bevacizumab to pembrolizumab improved objective response rate in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma. Study Details In the open-label trial, 48...

hepatobiliary cancer

TACE and Durvalumab/Bevacizumab in Unresectable HCC

In the phase III EMERALD-1 trial reported in The Lancet, Sangro et al found that transarterial chemoembolization (TACE) with durvalumab/bevacizumab improved progression-free survival vs placebo in patients with unresectable hepatocellular carcinoma (HCC) amenable to embolization.  Study Details In...

hepatobiliary cancer

Tiragolumab Plus Atezolizumab/Bevacizumab in Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma

In a phase Ib-II study (MORPHEUS-Liver) reported in The Lancet Oncology, Finn et al found that the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab/bevacizumab improved objective response rate in patients with unresectable, locally advanced, or metastatic hepatocellular...

gastroesophageal cancer

Perioperative Chemotherapy vs Preoperative Chemoradiotherapy in Resectable Locally Advanced Esophageal Carcinoma

In a German phase III trial (ESOPEC) reported in The New England Journal of Medicine, Hoeppner et al found that perioperative chemotherapy with fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) improved overall survival vs preoperative chemoradiotherapy in patients undergoing surgery for locally ...

lung cancer

Neoadjuvant Nivolumab/Ipilimumab vs Chemotherapy in Resectable NSCLC

As reported in the Journal of Clinical Oncology by Awad et al, exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs chemotherapy in the phase III CheckMate 816 trial found that nivolumab/ipilimumab was associated with numerically better event-free survival in patients with...

head and neck cancer

Addition of Cetuximab to Postoperative Radiotherapy in Intermediate-Risk Head and Neck Cancer

In a phase III trial (NRG/RTOG 0920) reported in Journal of Clinical Oncology, Machtay et al found that the addition of cetuximab to postoperative radiotherapy significantly improved disease-free survival—but not overall survival—in patients with completely resected, intermediate-risk, squamous...

hematologic malignancies

Clearance of Driver Mutations after Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis

In a German single-center study reported in The New England Journal of Medicine, Gagelmann et al determined that clearance of driver mutations after allogeneic hematopoietic stem-cell transplantation was associated with better outcomes in patients with myelofibrosis. Study Details The study...

skin cancer
survivorship

Melanoma Among Adult Survivors of Childhood Cancer

In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Rotz et al found that adult survivors of childhood cancers had a twofold increased risk of developing melanoma compared with the general population. Additionally, those with an invasive melanoma had a more...

hematologic malignancies
supportive care

Addition of Cyclophosphamide to Posttransplantation GVHD Prophylaxis

As reported in the Journal of Clinical Oncology by Holtan et al, the addition of cyclophosphamide to posttransplantation graft-vs-host disease (GVHD) prophylaxis with tacrolimus and mycophenolate mofetil was associated with improved patient-reported outcomes in the phase III BMT CTN 1703 trial in...

lung cancer

Advanced NSCLC With Brain Metastases: Potential Novel Therapeutic Option

In a Chinese phase II study (C-Brain) reported in The Lancet Oncology, Xu et al found that brain radiotherapy in combination with camrelizumab and platinum-doublet chemotherapy produced “promising” results in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with brain...

hepatobiliary cancer
solid tumors

Addition of Lenvatinib/Pembrolizumab to TACE in Unresectable Nonmetastatic HCC

As reported in The Lancet by Kudo et al, the phase III LEAP-012 trial has shown a significant progression-free survival benefit with the addition of lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) in patients with unresectable nonmetastatic hepatocellular carcinoma (HCC). A...

pancreatic cancer
genomics/genetics

Effect of KRAS Mutation Status on Treatment Outcomes in Metastatic Pancreatic Adenocarcinoma

In a study reported in JAMA Network Open, Norton et al found that KRAS G12D and G12V mutations were associated with worse outcomes compared with KRAS wild-type in patients with metastatic pancreatic adenocarcinoma. Study Details The retrospective cohort study used data from a nationwide U.S.-based ...

multiple myeloma

Talquetamab Plus Teclistamab in Relapsed or Refractory Multiple Myeloma

In a phase Ib-II study (RedirecTT-1) reported in The New England Journal of Medicine, Cohen et al found that the combination of the bispecific antibodies talquetamab (anti–G protein-coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) was associated with a...

breast cancer

Fulvestrant vs Anastrozole in Endocrine Therapy–Naive, HR-Positive, HER2-Negative Advanced Breast Cancer

As reported in the Journal of Clinical Oncology by John F.R. Robertson, PhD, and colleagues, the final overall survival analysis of the phase III FALCON trial showed no difference between fulvestrant vs anastrozole in patients with endocrine therapy–naive, hormone receptor–positive, HER2-negative...

colorectal cancer

Trastuzumab/Pertuzumab vs Cetuximab/Irinotecan in RAS/BRAF Wild-Type HER2-Positive Metastatic Colorectal Cancer

In a phase II trial (S1613) reported in the Journal of Clinical Oncology, Raghav et al found no difference in progression-free survival overall with trastuzumab/pertuzumab vs cetuximab/irinotecan in the second- or third-line treatment of RAS/BRAF wild-type HER2-positive metastatic colorectal...

cns cancers

Extent and Impact of Primary MMRD in Gliomas Among Children and AYAs

In a cohort study reported in The Lancet Oncology, Negm et al found that primary mismatch repair deficiency (MMRD) was associated with poor outcomes in children, adolescents, and young adults with gliomas. Study Details In the study, clinical and molecular data were collected from children,...

hematologic malignancies
lymphoma

Transplant-Free Treatment Approach in Relapsed Classical Hodgkin Lymphoma in Children and Adolescents and Young Adults

As reported in JAMA Oncology by Daw et al, findings in a cohort of the phase II CheckMate 744 trial indicated good outcomes with a response-adapted, transplantation-free treatment approach in children and adolescents and young adults (AYAs) with low-risk relapsed classical Hodgkin lymphoma (HL)....

gastroesophageal cancer
gastrointestinal cancer

Novel Antibody-Drug Conjugate in Advanced Gastric/Gastroesophageal Junction Cancer

In a Chinese phase I trial (KYM901) reported in The Lancet Oncology, Ruan et al found that CMG901—a first-in-class claudin 18.2–targeting antibody-drug conjugate—had manageable toxicity and activity in patients with advanced gastric or gastroesophageal junction (GEJ) cancer. CMG901 comprises a...

lymphoma

Addition of Brentuximab Vedotin to Lenalidomide/Rituximab in Relapsed or Refractory DLBCL

In an interim analysis of a phase III trial (ECHELON-3) reported in the Journal of Clinical Oncology, Bartlett et al found that the addition of brentuximab vedotin (BV) to lenalidomide and rituximab improved overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma...

lung cancer

Datopotamab Deruxtecan in Advanced or Metastatic NSCLC With Actionable Genomic Alterations

As reported in the Journal of Clinical Oncology by Sands et al, the phase II TROPION-Lung05 trial showed “encouraging activity” of datopotamab deruxtecan (Dato-DXd) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) with actionable genomic alterations whose disease progressed...

gynecologic cancers

Long-Term Follow-up of NRG258 Trial: Adjuvant Chemoradiation vs Chemotherapy in Locally Advanced Endometrial Carcinoma

As reported in the Journal of Clinical Oncology by Matei et al, the final overall survival analysis in the long-term follow-up of the phase III NRG258 trial has shown no difference between adjuvant chemoradiation (C-RT) vs chemotherapy (CT) in patients with locally advanced endometrial carcinoma....

lung cancer

Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemoradiotherapy (with or without adjuvant immunotherapy) was associated with activity in patients with locally advanced...

breast cancer

Adjuvant Dose-Dense vs Conventional Chemotherapy in Node-Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Filho et al, 12-year follow-up of the CALBG (Alliance) C9741 trial has shown a sustained advantage of adjuvant dose-dense vs conventional chemotherapy in disease-free and overall survival in patients with node-positive breast cancer. Study Details...

skin cancer
lymphoma

Use of Denileukin Diftitox-cxdl in Relapsed or Refractory CTCL

In a registrational trial reported in the Journal of Clinical Oncology, Foss et al found that denileukin diftitox (DD)-cxdl—a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2—was active in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)....

kidney cancer

Belzutifan Plus Cabozantinib as First-Line Treatment in Advanced Clear Cell Renal Cell Carcinoma

In a phase II trial (LITESPARK-003), reported in The Lancet Oncology, Choueiri et al found that the combination of belzutifan—a first-in-class HIF-2α inhibitor—and cabozantinib showed promising activity in the first-line treatment of patients with advanced clear cell renal cell carcinoma. Study...

gynecologic cancers

Final Overall Survival Results From SOLO3 Trial: Olaparib vs Nonplatinum Chemotherapy in Platinum-Sensitive BRCA-Mutated Relapsed Ovarian Cancer

As reported in the Journal of Clinical Oncology by Scambia et al, the final overall survival results of the phase III SOLO3 trial showed similar outcomes with olaparib vs non–platinum-based chemotherapy in patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer. In the initial report...

lymphoma

Nivolumab Plus AVD as Front-Line Therapy in Older Adults With Classical Hodgkin Lymphoma

In a phase I/II trial reported in the Journal of Clinical Oncology, Torka et al found that the addition of nivolumab to standard doxorubicin, vinblastine, and dacarbazine (N-AVD) was “highly effective” as front-line treatment for patients aged ≥ 60 with classical Hodgkin lymphoma. Study Details In...

prostate cancer

Effect on Ki67 Index of High Omega-3, Low Omega-6 Diet With Fish Oil in Prostate Cancer During Active Surveillance

In a single-institution phase II trial (CAPFISH-3) reported in the Journal of Clinical Oncology, Aronson et al found that men with prostate cancer on active surveillance had a significantly reduced Ki67 index on a high omega-3, low omega-6 fatty acid diet with fish oil capsules vs no dietary...

bladder cancer

Risk-Adapted Active Surveillance After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

In a phase II trial (RETAIN 1) reported in the Journal of Clinical Oncology, Geynisman et al found that risk-adapted active surveillance following neoadjuvant chemotherapy was associated with a high rate of metastasis-free survival in patients with muscle-invasive bladder cancer.   Study Details In ...

breast cancer

HRQOL With Endocrine Therapy vs Radiotherapy After Breast-Conserving Surgery in Older Women With Luminal A–Like Early Breast Cancer

As reported in The Lancet Oncology by Meattini et al, interim analysis of the phase III EUROPA trial indicated that endocrine therapy was associated with poorer health-related quality of life (HRQOL) outcomes vs radiotherapy after breast-conserving surgery in women aged ≥ 70 years with luminal...

skin cancer

RELATIVITY-047: Extended Analysis of Overall Survival With Nivolumab/Relatlimab vs Nivolumab in Previously Untreated Advanced Melanoma

In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma. The initial...

colorectal cancer

Trends in Early-Onset Colorectal Cancer

As reported in The Lancet Oncology by Sung et al, analysis of international population-based cancer registry data indicate an increase in incidence of colorectal cancer among younger persons (age < 50 years) in a majority of countries and territories examined. Study Details Colorectal cancer...

Advertisement

Advertisement




Advertisement